This coming week is likely to be a serious one in the fight against cholesterol. This covers a new class of drugs in the PCSK9 classification, and FDA panels are evaluating more than just one drug candidate.
A U.S. Food and Drug Administration (FDA) advisory panel is expected to meet on June 9 to consider the drug application of alirocumab from Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY). Amgen Inc. (NASDAQ: AMGN) also has a FDA advisory committee slated for June 10 for Repatha (evolocumab). Investors will also have to consider what this means for Pfizer Inc. (NYSE: PFE) with its PCSK9 trial underway.
Hey, check out all the research scientist jobs. Post your resume today!
